Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole
- PMID: 8979061
- DOI: 10.1016/s0016-5107(96)70055-x
Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole
Abstract
Background: Barrett's esophagus is mainly regarded as an acquired condition related to increased gastroesophageal reflux. Thus it is conceivable that abolition of acid reflux would lead to its regression. The aim of this study was to assess whether long-term treatment with high-dose omeprazole (60 mg/day) produces a consistent control of gastric acid production and normalizes the esophageal acid exposure, thus reducing the length of Barrett's epithelium.
Methods: Fourteen patients (8 men and 6 women, mean age 52 years) with histologic diagnosis of columnar epithelium longer than 3 cm in the distal part of the esophagus were enrolled and began receiving 60 mg of omeprazole in a single daily morning dose. Before therapy and after 6 and 12 months of therapy, all patients had endoscopy with four-quadrant biopsies at 2 cm intervals. A 24-hour esophagogastric pH recording was performed at entry and after 10 days, 6 months, and 12 months of treatment in all patients.
Results: The initial length of Barrett's epithelium (4.5 +/- 1.9 cm) was significantly reduced after 6 months (3.1 +/- 1.1; p < 0.01) and 12 months (2.1 +/- 1.6; p < 0.005) of treatment. Values were significantly lower at 12 than at 6 months (p < 0.03). The 24-hour mean gastric pH after 10 days (5.89 +/- 0.58), 6 months (5.71 +/- 0.55), and 12 months (5.54 +/- 0.76) of therapy was always higher (p < 0.001) than the basal level (1.9 +/- 0.49). No significant difference in gastric pH was seen over the treatment period. The 24-hour mean percent of time in which pH in the esophagus was below 4.0 decreased significantly (p < 0.001) from a basal rate of 29.4% to 3.5%, 3.0%, and 4.9% in the various time intervals of therapy. There was a normalization of esophageal acid exposure in all patients but two.
Conclusions: It can be concluded that the antisecretory effect of 60 mg/day of omeprazole is consistent and is kept constant throughout the entire 1-year treatment period. The consequent normalization of esophageal acid exposure in almost all patients in our series led to a partial, but significant, regression in the length of Barrett's epithelium.
Similar articles
-
The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus.Dig Dis Sci. 2013 Aug;58(8):2253-60. doi: 10.1007/s10620-013-2763-1. Epub 2013 Jul 4. Dig Dis Sci. 2013. PMID: 23824407
-
Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.Am J Gastroenterol. 1997 Apr;92(4):582-5. Am J Gastroenterol. 1997. PMID: 9128303
-
Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression.Endoscopy. 2002 Dec;34(12):950-5. doi: 10.1055/s-2002-35847. Endoscopy. 2002. PMID: 12471537 Clinical Trial.
-
Acid suppression in the long-term treatment of peptic stricture and Barrett's oesophagus.Digestion. 1992;51 Suppl 1:49-58. doi: 10.1159/000200916. Digestion. 1992. PMID: 1356869 Review.
-
Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association.Gastroenterology. 2016 Nov;151(5):822-835. doi: 10.1053/j.gastro.2016.09.040. Epub 2016 Oct 1. Gastroenterology. 2016. PMID: 27702561 Review.
Cited by
-
Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results.Gut. 1998 Dec;43(6):747-51. doi: 10.1136/gut.43.6.747. Gut. 1998. PMID: 9824599 Free PMC article.
-
The role of proton pump inhibitors in gastro-oesophageal reflux disease.Drugs. 2004;64(3):277-95. doi: 10.2165/00003495-200464030-00004. Drugs. 2004. PMID: 14871170 Review.
-
Barrett's esophagus in Japanese patients: its prevalence, form, and elongation.J Gastroenterol. 2008;43(12):928-34. doi: 10.1007/s00535-008-2261-y. Epub 2008 Dec 24. J Gastroenterol. 2008. PMID: 19107336
-
Long-term follow-up after complete ablation of Barrett's esophagus with argon plasma coagulation.World J Gastroenterol. 2005 Feb 28;11(8):1182-6. doi: 10.3748/wjg.v11.i8.1182. World J Gastroenterol. 2005. PMID: 15754401 Free PMC article. Clinical Trial.
-
Barrett's Epithelium to Esophageal Adenocarcinoma: Is There a "Point of No Return"?Front Genet. 2021 Sep 17;12:706706. doi: 10.3389/fgene.2021.706706. eCollection 2021. Front Genet. 2021. PMID: 34603373 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources